CIK 0001768446 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Climb Bio, Inc.
Sign in to watch- Ticker
- CLYM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832273741
- Phone
- 1-866-857-2596
- Business address
- 20 WILLIAM STREET, SUITE G50, WELLESLEY HILLS, MA
- Former names
- Eliem Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,366,820
- in 1 filing, $1.4M under 10b5-1 plans
Net −$1,366,820. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-27 | Thomas Stephen Basil Director | Grant or award | +103,907 | 103,907 | ||
| 2024-06-27 | Thomas Stephen Basil Director | Grant or award · Restricted Stock Units | +100,375 | 100,375 | ||
| 2024-06-26 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-06-26 | Levin Andrew David Executive Chairman | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2024-06-26 | Rosenberg Adam Joseph Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2024-06-26 | Dunn Judith Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2024-06-26 | Tate Simon Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2024-06-26 | Ratcliffe Liam Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2024-06-20 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Sale | −1,245 | $7.21 | $9K | 3,755 |
| 2024-06-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise | +5,000 | 5,000 | ||
| 2024-06-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise · Restricted Stock Units | −5,000 | 35,000 | ||
| 2024-04-05 | Morisset Valerie EVP, R&D AND CSO | Option exercise | +17,847 | $0.00 | $4 | 505,307 |
| 2024-04-05 | Morisset Valerie EVP, R&D AND CSO | Option exercise · Stock Option (Right to Buy) | −17,847 | 28,046 | ||
| 2024-03-18 | Pimblett Emily CHIEF ACCOUNTING OFFICER | Option exercise · Restricted Stock Units | +40,000 | 40,000 | ||
| 2023-09-20 | Morisset Valerie EVP, R&D AND CSO | Option exercise | +5,431 | $0.00 | $11 | 472,163 |
| 2023-09-20 | Morisset Valerie EVP, R&D AND CSO | Option exercise | +15,297 | $0.00 | $3 | 487,460 |
| 2023-09-20 | Morisset Valerie EVP, R&D AND CSO | Option exercise · Stock Option (Right to Buy) | −5,431 | 0 | ||
| 2023-09-20 | Morisset Valerie EVP, R&D AND CSO | Option exercise · Stock Option (Right to Buy) | −15,297 | 45,893 | ||
| 2023-05-18 | Tate Simon Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 | ||
| 2023-05-18 | Ratcliffe Liam Director | Grant or award · Stock Option (Right To Buy) | +10,000 | 10,000 |
Page 6 of 9 · 166 trades